Category page

VECTORS

Vectors

Vectors are invaluable tools for introducing foreign genetic material into cells for the propagation of the DNA molecules themselves or for production of phage virions. Genetically engineered vectors share common features such as an origin of replication, convenient cloning sites, and a selectable marker. Years prior to pioneering phage display technology. Dr. George P. Smith developed bacteriophage cloning vectors. Since then, two different types of vectors are utilized for phage display of peptides and antibodies, namely the bacteriophage vectors and phagemids.

Cell Origins carries bacteriophag e and phagemid vectors based on the original vectors created by Dr. George Smith. Many of our vectors include built-in tagging options to streamline your phage display selections and screening procedures.

Bacteriophage Vectors


Filamentous bacteriophage vectors carry a modified version of the complete phage genome. Apart from the wild-type genes, these vectors typically contain an antibiotic selection gene and a hybrid gene encoding a recombinant fusion of the foreign peptide or antibody with the coat protein. By expressing both the wild type and hybrid genes, the display of the foreign polypeptide is intentionally limited, which can be advantageous as it encourages the selection of high-affinity peptide sequences. While bacteriophage vectors are generally unsuitable for displaying antibodies or antibody fragments due to their larger size that hampers E. coli infection and complicates transformation, they have been successfully utilized in peptide phage display. Notably, bacteriophage vectors possess the required genes for phage particle replication in their own genome, eliminating the need for helper phages during propagation.

Product Name Cat. Number
Fd-tet COV0001
F3TR1 COV0002
fUSE5 COV0003
f88-4 COV0004

Phagemid Vectors


Phagemids are plasmid-based vectors that possess both phage and bacterial origins of replication, along with an antibiotic selection gene. Typically, a phagemid vector encodes a coat protein (either pIII or pVIII) fused with a foreign DNA sequence. This fusion enables the display of full-length antibodies, antibody fragments, nanobodies, or peptides. Phagemids can replicate in E. coli without the need for helper phages. However, for phage clone production, helper phages are vital as they contain essential genes required for phage particle assembly and release. A significant advantage of phagemids is their compact vector DNA, facilitating easy transformation in E. coli . The efficiency of E. coli transformation directly influences the diversity of the phage display library, making it a crucial factor when selecting a suitable vector for phage display. Furthermore, the small size of phagemid vectors enables convenient manipulation using recombinant DNA technology. Unlike bacteriophage vectors, phagemids excel at displaying large proteins such as full-length antibodies and antibody fragments, as their propagation in E. coli relies on a separate helper phage.

Contact us for custom phagemid vectors.


References


Axiak-Bechtel, S. M., Leach, S. B., Scholten, D. G., Newton-Northup, J. R., Johnson, B. J., Durham, H. E., Gruber, K. A., Callahan, M. F. (2021). Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs. Pharmacology Research & Perspectives. Vol. 9(3)

Asar, M., Franco, A., Soendergaard, M. (2020). Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides. Biomolecules. 10(5), 714

Asar, M., Gunby, T., Franco, A., Woodson, C., Soendergaard, Mette. (2020). Identification of an Indiscriminate Peptide by Phage Display Technology. The FASEB Journal 34:1_supplement, 1-1

Asar, M., Newton-Northup, J., Deutscher, S., Soendergaard, M. (2019). Ovarian Cancer Targeting Phage for In Vivo Near-Infrared Optical Imaging. Diagnostics, 9, 183.

Newton-Northup, J.R., and Deutscher, S.L. (2017). Bacteriophage for the Development of Novel Tumor-Targeting Agents with Specific Pharmacokinetics and Imaging Applications. Methods in Molecular Biology in Biosensors and Biodetection.

Newton-Northup, J.R., and Deutscher, S.L.. (2016). Cytotoxic Tumor-Targeting Peptides From In Vivo Phage Display. Combinatorial Chemistry & High Throughput Screening. Vol. 19(5): 370–377

García, M. F., Zhang, X., Shah, M., Newton-Northup, J., Cabral, P., Cerecetto, H., and Quinn, T. (2016). 99mTc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging. Bioorganic & Medicinal Chemistry. Vol. 24(6): 1209–1215

Newton-Northup, J.R., Dickerson, M.T., Kumar, S.R., Smith, G.P., Quinn, T.P., And Deutscher, S.L. (2014) In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles. Molecular Imaging and Biology. 16(6), 854-864.

Soendergaard M., Newton-Northup J. R., Deutscher S. L. (2014): In Vivo Phage Display Selection of an Ovarian Cancer Targeting Peptide for SPECT/CT Imaging. American Journal of Nuclear Medicine and Molecular Imaging. 4(6): 561–570.

Soendergaard, M., Newton-Northup, J.R., and Deutscher, S.L. (2014) In vitro high throughput phage display selection of ovarian cancer avid phage clones for near-infrared optical imaging. Combinatorial Chemistry and High Throughput Screening. 17(10).

Newton-Northup, J.R., and Deutscher, S.L. (2013). Contending With Target Unrelated Peptides from Phage Display. Journal of Molecular Imaging & Dynamics. Vol. 2(2)

Newton-Northup, J. R., Dickerson, M. T., Ma, L., Besch-Williford, C. L., Deutscher, S. L. (2013). Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide. Clinical & Experimental Metastasis. Vol. 30:119–132

Soendergaard, M., Newton-Northup, J.R., Palmier, M.O., and Deutscher, S.L. (2011) Peptide phage display for discovery of novel biomarkers for imaging and therapy of cell subpopulations in ovarian cancer. Journal of Molecular Biomarkers and Diagnosis, S:2.

Newton-Northup, J.R., Figueroa, S.D., and Deutscher, S.L. (2010). Streamlined in vivo selection and screening of human prostate carcinoma avid phage particles for development of peptide based in vivo tumor imaging agents. Combinatorial chemistry & high throughput screening. 14(1):9-21

Deutscher, S. L., Dickerson, M., Gui, G., Newton, J., Holm, J. E., Vogeltanz-Holm, N., Kliethermes, B., Hewett, J. E., Kumar, S. R., Quinn, T. P., Sauter, E. R. (2010). Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy. BMC Cancer. Vol. 10(519)

Newton-Northup, J.R., Figueroa, S.D., Quinn, T. P., and Deutscher, S.L. (2009). Bifunctional phage-based pretargeted imaging of human prostate carcinoma. Nuclear Medicine and Biology. Vol. 36(7):789-800

Jin, X., Newton, J. R., Montgomery, S., Smith, G. P. (2009). A generalized kinetic model for amine modification of proteins with application to phage display. Biotechniques. Vol. 46(3):175-182

Newton-Northup, J.R., and Deutscher, S.L. (2009). In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents. Methods in Molecular Biology. Vol. 504:275-90

Newton-Northup, J.R., and Deutscher, S.L. (2008). Peptide Phage Display. Handbook of Experimental Pharmacology: Molecular Imaging I. Vol. 185 Pt 2:145-163.

Newton, J. R., Miao, Yubin., Deutscher, S. L., and Quinn, T. P. (2007). Melanoma Imaging with Pretargeted Bivalent Bacteriophage. Journal of Nuclear Medicine. Vol. 48(3):429-436

Newton, J. R., Kelly, K. A., Mahmood, U., Weissleder, R., and Deutscher, S. L. (2006) In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia. 8(9), 772-780

Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, Hashem AM. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Front Immunol. 2020 Aug 28;11:1986. doi: 10.3389/fimmu.2020.01986. PMID: 32983137; PMCID: PMC7485114.

Andrieu J, Re F, Russo L, Nicotra F. Phage-displayed peptides targeting specific tissues and organs. J Drug Target. 2019 Jun-Jul;27(5-6):555-565. doi: 10.1080/1061186X.2018.1531419. Epub 2018 Oct 24. PMID: 30281393.

Bazan J, Całkosiński I, Gamian A. Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccin Immunother. 2012 Dec 1;8(12):1817-28. doi: 10.4161/hv.21703. Epub 2012 Aug 21. PMID: 22906939; PMCID: PMC3656071.

Kumar R, Parray HA, Shrivastava T, Sinha S, Luthra K. Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies. Int J Biol Macromol. 2019 Aug 15;135:907-918. doi: 10.1016/j.ijbiomac.2019.06.006. Epub 2019 Jun 3. PMID: 31170490.

Ledsgaard L, Kilstrup M, Karatt-Vellatt A, McCafferty J, Laustsen AH. Basics of Antibody Phage Display Technology. Toxins (Basel). 2018 Jun 9;10(6):236. doi: 10.3390/toxins10060236. PMID: 29890762; PMCID: PMC6024766.

Saw PE, Song EW. Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein Cell. 2019 Nov;10(11):787-807. doi: 10.1007/s13238-019-0639-7. Epub 2019 May 28. PMID: 31140150; PMCID: PMC6834755.

Sioud M. Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics. Mol Biotechnol. 2019 Apr;61(4):286-303. doi: 10.1007/s12033-019-00156-8. PMID: 30729435.

Wu CH, Liu IJ, Lu RM, Wu HC. Advancement and applications of peptide phage display technology in biomedical science. J Biomed Sci. 2016 Jan 19;23:8. doi: 10.1186/s12929-016-0223-x. PMID: 26786672; PMCID: PMC4717660.

Share by: